ReviewJournal of personalized medicine2022
Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases: An OECD Best Practice for Integrated Care for Chronic Diseases.Clinical and translational allergy · 2026Article
- Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.Current allergy and asthma reports · 2026Review
- Treatment response and determinants of asthma control in Eastern Africa.BMC pulmonary medicine · 2026Article
- Targeted metabolomic analysis of exhaled breath condensate before and after bronchial provocation by eucapnic voluntary hyperventilation in adolescents with asthma: an exploratory study.Respiratory research & clinical practice · 2026Article
- Thrombophilic Changes and Hematological Complications in Asthmatic Patients with COVID-19: A Systematic Review.Diseases (Basel, Switzerland) · 2025Review
- Stachydrine Showing Metabolic Changes in Mice Exposed to House Dust Mites Ameliorates Allergen-Induced Inflammation.Nutrients · 2025Article
- Menstrual blood serum extracellular vesicles reveal novel molecular biomarkers and potential endotypes of unexplained infertility.Scientific reports · 2025Article
- Review
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Association of LPCAT1-rs8352 genetic variant with susceptibility and severity of pediatric bronchial asthma: a case-control study.BMC pediatrics · 2025Article
- Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action.Journal of asthma and allergy · 2025Review
- Endotype-driven decisions in choosing a biologic for airway diseases.Frontiers in allergy · 2025Review
- Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.Scientific reports · 2024Article
- Exploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum.International journal of molecular sciences · 2024Article
- Review
- Machine Learning Approaches to Predict Asthma Exacerbations: A Narrative Review.Advances in therapy · 2024Review
- Obese Asthma Phenotype Is Associated with hsa-miR-26a-1-3p and hsa-miR-376a-3p Modulating the IGF Axis.International journal of molecular sciences · 2023Article
- Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles.International journal of molecular sciences · 2023Review
- Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic agents have been developed towards a personalized approach to asthma management. This review will focus on different eosinophilic phenotypes and Th2-associated endotypes with eosinophilic inflammation. Additionally, airway remodeling is analyzed as a key feature of asthmatic eosinophilic endotypes. In addition, evidence of biomarkers is examined with a predictive value to identify patients with severe, uncontrolled asthma who may benefit from new treatment options. Finally, there will be a discussion on the results from clinical trials regarding severe eosinophilic asthma and how the inhibition of the eosinophilic pathway by targeted treatments has led to the reduction of recurrent exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.